PUBLISHER: Grand View Research | PRODUCT CODE: 1529604
PUBLISHER: Grand View Research | PRODUCT CODE: 1529604
The global smart inhalers market size is expected to reach USD 53.3 billion by 2030 and is projected to grow at a CAGR of 19.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the smart inhaler market is driven by several key factors, including the rising prevalence of respiratory diseases, increased awareness initiatives, the integration of digital technologies in medical devices, and the development of advanced products by market players. The global rise in chronic respiratory diseases, exacerbated by pollution and low immunity, particularly asthma and COPD, fuels demand for inhalers. According to the American Lung Association, approximately 11.7 million people in the U.S., or 4.6% of adults, were diagnosed with COPD in 2022, which is expected to boost demand for technologically advanced inhalers.
Smart inhalers offer benefits over traditional ones, such as dosage reminders, health tracking, adherence support, and data-driven insights. Market players are actively investing in innovative solutions to meet evolving demands. For example, Aptar Pharma introduced HeroTracker Sense in April 2022, transforming conventional inhalers into smart devices, and partnered with Lupin Limited in January 2020 to launch the ADHERO device, which tracks medication usage via the "MyAdhero" application. These advancements are anticipated to drive global demand for smart inhalers.
In addition, government and private sector initiatives are enhancing awareness about respiratory diseases. The American Lung Association's "Addressing COPD" project, launched in November 2022, aims to improve the care of 12.5 million COPD patients in the U.S. Such efforts, combined with the growing availability of advanced devices, significantly contribute to the smart inhaler market's growth.